Hard-charg­ing GSK re­search chief Hal Bar­ron touts im­proved an­ti-BC­MA da­ta, aim­ing for fast ap­pli­ca­tions

Glax­o­SmithK­line R&D chief Hal Bar­ron tout­ed a fresh set of up­dat­ed da­ta on their an­ti-BC­MA an­ti­body drug con­ju­gate GSK2857916 on Thurs­day, point­ing to a sol­id 60% re­sponse rate from their DREAMM-1 study on mul­ti­ple myelo­ma as he bur­nished the phar­ma gi­ant’s im­proved late-stage prospects in on­col­o­gy.

Im­age: Hal Bar­ron. GSK

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER